APP and fatty liver disease: Interestingly, lipid metabolism disorders in APP/PS1 mice treated with Akk were significantly improved, showing a decrease in serum Chol and TG levels, and hepatic fat scores showed ameliorative hepatic steatosis (Fig. 2e, f, p < 0.05, respectively).